Article Versions Notes

Sun X, Zhen Z, Guo Y, Gao Y, Wang J, Zhang Y, Zhu J, Lu S, Sun F, Huang J, et al. Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies. Cancers. 2021; 13(14):3494. https://doi.org/10.3390/cancers13143494

Sun, Xiaofei, Zijun Zhen, Ying Guo, Yuanhong Gao, Juan Wang, Yu Zhang, Jia Zhu, Suying Lu, Feifei Sun, Junting Huang, and et al. 2021. "Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies" Cancers 13, no. 14: 3494. https://doi.org/10.3390/cancers13143494

Sun, X., Zhen, Z., Guo, Y., Gao, Y., Wang, J., Zhang, Y., Zhu, J., Lu, S., Sun, F., Huang, J., Cai, R., Zhang, Y., Liu, J., Xiao, Z., Zeng, S., & Liu, Z. (2021). Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies. Cancers, 13(14), 3494. https://doi.org/10.3390/cancers13143494